PGEN Short Interest Hits Yearly High as Stock Surges 12%

Short sellers have built their largest position in PGEN in at least a year, even as the stock climbed sharply through the week.

Short interest reached 13.8% of the free float as of October 29, up roughly 21% over the past month. The sharpest acceleration came in mid-October: borrowed shares jumped from around 40 million to nearly 48 million in the space of a single week around October 9, a move of roughly 18% in borrowed shares that has held since. The official FINRA fortnightly figure, settled at October 15, put short shares at 46.4 million with days-to-cover at 10.2, confirming the position is not small and would take time to unwind at normal trading volumes.

The borrow market tells a more relaxed story than the short interest level alone might suggest. Availability has loosened considerably over the past week, rising to 98.8% from around 78% a week earlier, meaning nearly as many shares are available to borrow as are already borrowed. Cost to borrow is a low 0.53%, down 8% on the week, so new short positions can be established cheaply. The ORTEX short score, which aggregates lending-market signals, sits at 77.7 out of 100, elevated and near its highest reading of the past two weeks, though the loosening availability tempers any squeeze read. Options positioning has shifted more defensive in recent days: the put/call ratio moved to 0.09, nearly two standard deviations above its 20-day average of 0.077, still a low absolute level but the highest the ratio has been in months, and worth watching given earnings are four days away on November 4.

Coverage on PGEN is constructive but thin. Two analysts carry buy ratings, with B. Riley initiating at Buy with a $12 target in late September and HC Wainwright maintaining Buy after raising its target to $18 following the August earnings print. The mean target of $13.65 implies roughly 97% upside to the $6.94 close. The stock is loss-making, with a negative PE, and the price-to-book multiple of 2.46 has expanded about 17% over the past 30 days alongside the price recovery. The ORTEX short score rank sits in the bottom 5th percentile of the universe, meaning the lending-market pressure on this name is more intense than nearly all comparable stocks.

The ownership picture adds a layer of complexity that is unusual for a stock of this size. Randal J. Kirk holds a Schedule 13D activist stake last disclosed at 35.9% of the class, down from 38.1% previously, filed as recently as March 2026. An activist on the 13D register is one of the most consequential facts on the cap table: it signals intent beyond passive ownership. Patient Capital Management holds a further 10.2% on a 13G, and the William Miller Living Trust holds 9.2%. Between the three of them, more than half the company's shares are held in disclosed concentrated positions. BlackRock added 1.9 million shares in the quarter to September 30, State Street added 1.1 million, and Vanguard added 855,000, suggesting passive index flows have also been buying. On the insider side, the most meaningful recent open-market activity was a director sale: Jeffrey Kindler sold 185,000 shares at $7.44 on August 26 for $1.4 million, a discretionary transaction without a 10b5-1 plan. The CFO's September transactions were option exercises, not open-market purchases, and carry less signal. Net insider activity over the past 90 days totals a net sale of roughly $6.8 million in value.

Retail attention has also picked up. The ORTEX alt-data layer shows Wikipedia page views running at a z-score of 1.7 above the company's own 90-day average as of mid-October, consistent with the stock's 12.1% weekly gain drawing broader notice. Peers moved in a wide range over the same week: ABSI gained 21%, SVRA added 14%, and XGN climbed 18%, while TWST fell 12% and CRSP dropped 5%. PGEN's 12.1% weekly advance sits in the upper half of that group but is not an outlier, suggesting broader biotech momentum contributed to the move rather than PGEN-specific news alone.

The next scheduled catalyst is the November 4 earnings report, the first since August's print produced a 5.4% one-day decline followed by a 4.4% five-day recovery. Short interest at a yearly high, a high short score, and a PCR moving above its recent range are the metrics to track between now and that date.